Introduction: Tuberculosis (TB) is one of the most common infectious illnesses and one of the major causes of mortality. The combined economic and health cost of tuberculosis (TB) and diabetic mellitus (DM) is a big problem. Anti-TB medication may put patients at risk for developing an adverse pharmacological response (ADR). More research is needed to determine the effect of DM on anti-TB ADR.
Methods: A cross-sectional research was conducted, with patients being followed for at least two years. Three Malaysian teaching hospitals were used to choose patients. Patients with tuberculosis and diabetic patients with tuberculosis were separated into two groups of 200 people each. At the start and end of the trial, data was taken from participants' medical records. The frequency of major adverse drug reactions (ADRs) that necessitated dosage adjustments was determined.
Results: ADR was noted in our participants' medical records and validated using a technique called Challenge. ADR was found in 16.5 percent of DM-TB patients and 14.8 percent of TB-only patients, respectively, although the difference was not significant (Fisher E.T: P > 0.05). Streptomycin therapy was associated with a higher rate of adverse events, which may be due to the drug's unpleasant administration. The therapy with isoniazid had the lowest rate of ADR.
Conclusion: While ADR was common in DM-TB patients, it was not statistically different from that of TB-only patients.
Please click here:https://journaljamps.com/index.php/JAMPS/article/view/30183
No comments:
Post a Comment